Rossari Biotech (ROSSARI) investor relations material

Executive summary

• Achieved record consolidated revenue growth of 28% year-over-year in Q1 FY27, driven by strong domestic momentum and expanding international presence.

• All core business segments—HPPC, TSC, and AHN—delivered robust YoY growth of 28%, 28%, and 27%, respectively.

• Growth supported by diversified portfolio, disciplined execution, innovation, and new R&D center, with expanded product offerings in HPPC, textile, and agrochemical segments.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were reviewed and approved by the Board and Audit Committee, with a limited review by statutory auditors.

• Strategic focus on margin improvement, operational efficiency, and rationalization of non-core and lower-margin businesses.

Financial highlights

• Q1 FY27 consolidated revenue from operations: ₹697.2 crore (₹6,972 million), up 28% YoY; highest-ever quarterly revenue.

• EBITDA: ₹80.6 crore, up 18.7% YoY; EBITDA margin at 11.6% (down 90 bps YoY).

• PAT: ₹35.1 crore (₹350.95 million), up 4.5% YoY; PAT margin at 5.0%.

• EPS (diluted) for Q1 FY27 was ₹6.3, compared to ₹6.1 in Q1 FY26.

• Export revenue: INR 160 crore, 23-26% of total revenue, up 21% YoY.

Outlook and guidance

• Management maintains 15% annual revenue growth guidance for FY27, despite Q1 outperformance, citing global volatility and raw material uncertainties.

• Margin improvement expected as capacity utilization rises, product mix improves, and non-core B2C businesses are exited.

• Steady-state EBITDA margin target of 14-15% over the next two years as business mix recalibrates.

• Focus remains on disciplined execution, innovation, and profitable growth for FY27.

• Pharma business expected to contribute INR 30-50 crore in FY27, ramping up further post-compliance.